Tags

Type your tag names separated by a space and hit enter

[From external to implantable insulin pump, can we close the loop?].
Diabetes Metab. 2002 Sep; 28(4 Pt 2):2S19-2S25.DM

Abstract

The project to finalize a 'closed loop' insulin delivery according to blood glucose level, i.e. an implanted artificial beta cell, is born from the development of the first miniaturized portable insulin pumps during the 1970s. Continuous improvements in micro-electronics, as well as in the development of biomaterials and stable insulin solutions, have led to the availability of implantable pumps able to infuse insulin by the peritoneal route, in a continuous and programmable way, for several years. These systems represent the most efficient and physiological mode of insulin therapy at the present time. More recently, we have demonstrated during clinical trials that intravascular, implantable, glucose sensors using glucose-oxidase were able to measure with good accuracy real-time blood glucose for several months. The combination of these two devices to form a prototype of implantable artificial beta cell, designated as Long Term Sensor System, allowed us to perform the first trials of closed-loop insulin delivery according to sensor signal for periods of 48 hours in type 1 diabetic patients. This mode of functioning appeared to be feasible and able to establish glucose control closer to physiology than the use of implantable pumps in open-loop, i.e. by adapting insulin delivery according to capillary blood glucose. Although algorithms tuning automated insulin delivery are improvable, the success of these initial trials materializes the perspective of a possible restoration of physiological insulin function by the mean of an implanted artificial beta cell in diabetic patients.

Authors+Show Affiliations

Service des Maladies Endocriniennes, Hôpital Lapeyronie, 34295 Montpellier Cedex 5, France. e-renard@chu-montpellier.frNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

12442060

Citation

Renard, E, et al. "[From External to Implantable Insulin Pump, Can We Close the Loop?]." Diabetes & Metabolism, vol. 28, no. 4 Pt 2, 2002, pp. 2S19-2S25.
Renard E, Costalat G, Bringer J. [From external to implantable insulin pump, can we close the loop?]. Diabetes Metab. 2002;28(4 Pt 2):2S19-2S25.
Renard, E., Costalat, G., & Bringer, J. (2002). [From external to implantable insulin pump, can we close the loop?]. Diabetes & Metabolism, 28(4 Pt 2), 2S19-2S25.
Renard E, Costalat G, Bringer J. [From External to Implantable Insulin Pump, Can We Close the Loop?]. Diabetes Metab. 2002;28(4 Pt 2):2S19-2S25. PubMed PMID: 12442060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [From external to implantable insulin pump, can we close the loop?]. AU - Renard,E, AU - Costalat,G, AU - Bringer,J, PY - 2002/11/21/pubmed PY - 2002/12/21/medline PY - 2002/11/21/entrez SP - 2S19 EP - 2S25 JF - Diabetes & metabolism JO - Diabetes Metab VL - 28 IS - 4 Pt 2 N2 - The project to finalize a 'closed loop' insulin delivery according to blood glucose level, i.e. an implanted artificial beta cell, is born from the development of the first miniaturized portable insulin pumps during the 1970s. Continuous improvements in micro-electronics, as well as in the development of biomaterials and stable insulin solutions, have led to the availability of implantable pumps able to infuse insulin by the peritoneal route, in a continuous and programmable way, for several years. These systems represent the most efficient and physiological mode of insulin therapy at the present time. More recently, we have demonstrated during clinical trials that intravascular, implantable, glucose sensors using glucose-oxidase were able to measure with good accuracy real-time blood glucose for several months. The combination of these two devices to form a prototype of implantable artificial beta cell, designated as Long Term Sensor System, allowed us to perform the first trials of closed-loop insulin delivery according to sensor signal for periods of 48 hours in type 1 diabetic patients. This mode of functioning appeared to be feasible and able to establish glucose control closer to physiology than the use of implantable pumps in open-loop, i.e. by adapting insulin delivery according to capillary blood glucose. Although algorithms tuning automated insulin delivery are improvable, the success of these initial trials materializes the perspective of a possible restoration of physiological insulin function by the mean of an implanted artificial beta cell in diabetic patients. SN - 1262-3636 UR - https://www.unboundmedicine.com/medline/citation/12442060/[From_external_to_implantable_insulin_pump_can_we_close_the_loop]_ L2 - https://medlineplus.gov/bloodsugar.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.